CNS Pharmaceuticals Files 10-K/A Amendment
Ticker: CNSP · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
CNS Pharmaceuticals filed an amendment to its 2024 10-K, updating Part III. Check for details.
AI Summary
CNS Pharmaceuticals, Inc. filed an amendment (10-K/A) on April 30, 2025, to its annual report for the fiscal year ended December 31, 2024. This amendment specifically addresses Part III of the report. The company, incorporated in Nevada with its principal executive offices in Houston, Texas, operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates an update or correction to the company's annual report, which could contain important information for investors regarding the company's financial health and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to SEC filings can sometimes indicate previously undisclosed issues or a need for clarification, warranting a medium risk assessment until the specific changes are fully understood.
Key Numbers
- 2024 — Fiscal Year End (The amendment pertains to the annual report for this fiscal year.)
- 10-K/A — Filing Type (This is an Amendment No. 1 to the annual report.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- 2024-12-31 (date) — Fiscal Year End
- 2025-04-30 (date) — Filing Date
- 2100 West Loop South, Suite 900, Houston, Texas 77027 (address) — Principal Executive Offices
- Nevada (jurisdiction) — State of Incorporation
FAQ
What specific information is being amended in Part III of the 10-K filing?
The filing indicates that Amendment No. 1 is to Amend Part III of the Form 10-K for the fiscal year ended December 31, 2024. Specific details of the amendment are not provided in this header information.
When was the original 10-K filed, and what is the purpose of this amendment?
The original 10-K was for the fiscal year ended December 31, 2024. This filing, dated April 30, 2025, is Amendment No. 1, specifically to amend Part III.
What is the primary business of CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. operates in the 'PHARMACEUTICAL PREPARATIONS' industry, with the Standard Industrial Classification code 2834.
Where are CNS Pharmaceuticals, Inc.'s principal executive offices located?
The company's principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
In which U.S. state was CNS Pharmaceuticals, Inc. incorporated?
CNS Pharmaceuticals, Inc. was incorporated in Nevada.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding CNS Pharmaceuticals, Inc. (CNSP).